FDA Approves First IV Treatment for Migraine Prevention

News
Article

Eptinezumab-jjmr (Vyepti, Lundbeck) decreased mean monthly migraine days in adult patients in 2 phase 3 clinical trials.

FDA Approval

Officials with the FDA have approved eptinezumab-jjmr (Vyepti, Lundbeck), the first intravenous (IV) treatment for the prevention of migraine in adults,  according to a press release.

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. The recommended dose is 100 mg every 3 months, but some patients may benefit from a 300-mg dose.

The approval is based on results from 2 phase 3 clinical trials: the PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine. In both studies, patients recieved either a placebo, eptinezumab-jjmr 100 mg, or eptinezumab-jjmr 300 mg. The primary endpoint was the change from baseline in mean monthly migraine day (MMD) over months 1 to 3. Patients were allowed to use concurrent acute migraine or headache medication, including migraine-specific medications, during the study.

Overall, the clinical trials demonstrated a treatment benefit over placebo for both doses of eptinezumab-jjmr as early as day 1 post-infusion. Additionally, the percentage of patients experiencing a migraine was lower for eptinezumab-jjmr than with placebo for most of the first 7 days. Among 2076 patients who received at least 1 dose of eptinezumab-jjmr, the most common adverse reactions were nasopharyngitis and hypersensitivity. In both trials, 1.9% of patients treated with eptinezumab-jjmr discontinued due to adverse reactions.

PROMISE-1 included a total of 665 patients who were randomized to 1 of the 3 treatment groups every 3 months for a 12-month period.

The results showed:

  • Mean migraine frequency at baseline was approximately 8.6 migraine days per month and was similar across treatment groups.

  • Mean change from baseline in MMD with eptinezumab-jjmr compared with placebo months 1 to 3: -3.9 days for 100 mg (p=0.018), -4.3 days for 300 mg (p<0.001), and -3.2 days for placebo.

  • Percent responders with at least 50% reduction in MMD in months 1 to 3 compared with placebo: 49.8% for 100 mg (nominal statistical significance p=0.009), 56.3% for 300 mg (p<0.001), and 37.4% for placebo.

  • Percent responders with at least 75% in MMD in months 1 to 3: 22.2% for 100 mg (p=not statistically significant), 29.7% for 300 mg (p<0.001), and 16.2% for placebo.

  • Greater percentage of placebo-treated patients had migraine on most days during the first 7 days of treatment compared with eptinezumab-jjmr-treated patients.

 In PROMISE-2, a total of 1072 patents were randomized to receive a placebo, 100-mg eptinezumab-jjmr, or 300-mg eptinezumab-jjmr every 3 months for 6 months. According to the data:

  • Mean migraine frequency at baseline was approximately 16.1 migraine days per month and was similar across treatment groups.

  • Mean change from baseline in MMD compared with placebo months 1 to 3: 7.7 days for 100 mg (p<0.001), -8.2 days for 300 mg (p<0.001), and -5.6 days for placebo.

  • Percent responders with at least 50% reduction in MMD in months 1 to 3 compared with placebo: 57.6% for 100 mg (p<0.001), 33.1% for 300 mg (p<0.001), and 15% for placebo.

  • Greater percentage of placebo-treated patients had migraine on each individual day during the first 7 days of treatment compared with eptinezumab-jjmr-treated patients.

“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine improvement through 6 months, which is clinically meaningful to both physicians and patients,” Dr Peter Goadsby, a professor of neurology at King’s College, London and the University of California, San Francisco, said in a statement. “Vyepti is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”

Eptinezumab-jjmr will be available in April 2020, according to Lundbeck.

 

References:

1. FDA approves Lundbeck’s VYEPTI (eptinezumab-jjmr)–the first and only intravenous preventive treatment for migraine [news release]. Lundbeck’s website. https://www.newsroom.lundbeckus.com/news-release/2020/fda-approves-lundbecks-vyepti-eptinezumab-jjmr-for-migraine. Accessed February 24, 2020.

 

 

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.